Article information
Full text is only aviable in PDF
bibliografía
[1.]
N.R. Anthonisen, J. Manfreda, P.W. Warren, E.S. Hersfield, G.K. Harding, N.A. Nelson.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med, 106 (1987), pp. 196-204
[2.]
C. Llor, M. Mayer.
Recomendaciones en el uso de antimicrobianos en atención primaria, Barcelona, 3.a ed,
[3.]
F. Sánchez, J. Mensa, A. Martínez, E. García, F. Marco, J. González, et al.
Is azythromycin the first-choice macrolide for treatment of community-acquired pneumonia?.
Clin Infect Dis, 36 (2003), pp. 1239-1245
[4.]
J.R. Lonks, J. Garau, L. Gómez, M. Xercavins, A. Ochoa de Echagen, I.F. Gareen, et al.
Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.
Clin Infect Dis, 35 (2002), pp. 556-564
[5.]
J. Andrews, D. Honeybourne, O. Khair, et al.
Penetration of telithromycin (HMR 3647) into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM) following multiple oral doses (resumen 658),
[6.]
M. Aubier, P.M. Aldons, A. Leak, et al.
Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis in patients with COPD [resumen 2.241],
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica
